Anhui Huaheng Biotechnology Co., Ltd. (SHA:688639)
32.26
-0.10 (-0.31%)
Mar 10, 2026, 11:29 AM CST
SHA:688639 Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Operating Revenue | 2,886 | 1,805 | 1,704 | 1,220 | 841.86 | Upgrade
|
| Other Revenue | - | 372.99 | 234.23 | 198.65 | 112.23 | Upgrade
|
| Revenue | 2,886 | 2,178 | 1,938 | 1,419 | 954.1 | Upgrade
|
| Revenue Growth (YoY) | 32.50% | 12.37% | 36.63% | 48.69% | 95.81% | Upgrade
|
| Cost of Revenue | - | 1,638 | 1,156 | 870.26 | 646 | Upgrade
|
| Gross Profit | 2,886 | 539.66 | 782.37 | 548.39 | 308.1 | Upgrade
|
| Selling, General & Admin | - | 221.48 | 172.08 | 142.22 | 79.93 | Upgrade
|
| Research & Development | - | 124.05 | 108.82 | 78.61 | 52.84 | Upgrade
|
| Other Operating Expenses | 2,760 | -13.41 | 4.55 | 7.97 | 6.58 | Upgrade
|
| Operating Expenses | 2,760 | 330.9 | 285.77 | 231.29 | 139.03 | Upgrade
|
| Operating Income | 125.82 | 208.75 | 496.6 | 317.1 | 169.06 | Upgrade
|
| Interest Expense | - | -37.87 | -10.64 | -0.54 | -1.11 | Upgrade
|
| Interest & Investment Income | - | 5.25 | 5.91 | 10.64 | 7.5 | Upgrade
|
| Currency Exchange Gain (Loss) | - | 14.04 | 7.06 | 5.43 | -0.16 | Upgrade
|
| Other Non Operating Income (Expenses) | -4.1 | -3.3 | -2.66 | -0.59 | -0.39 | Upgrade
|
| EBT Excluding Unusual Items | 121.72 | 186.87 | 496.27 | 332.04 | 174.91 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | -0.31 | -0.75 | 1.06 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | -0.37 | -2.67 | -4.62 | -0.36 | Upgrade
|
| Asset Writedown | - | - | - | - | -5.61 | Upgrade
|
| Other Unusual Items | - | 14.9 | 12.98 | 16.32 | 20.78 | Upgrade
|
| Pretax Income | 121.72 | 201.41 | 506.27 | 342.98 | 190.79 | Upgrade
|
| Income Tax Expense | -9.09 | 16.85 | 59.67 | 23.64 | 22.55 | Upgrade
|
| Earnings From Continuing Operations | 130.82 | 184.56 | 446.6 | 319.34 | 168.24 | Upgrade
|
| Minority Interest in Earnings | - | 4.96 | 2.46 | 0.69 | - | Upgrade
|
| Net Income | 130.82 | 189.52 | 449.06 | 320.03 | 168.24 | Upgrade
|
| Net Income to Common | 130.82 | 189.52 | 449.06 | 320.03 | 168.24 | Upgrade
|
| Net Income Growth | -30.98% | -57.80% | 40.32% | 90.23% | 38.92% | Upgrade
|
| Shares Outstanding (Basic) | 252 | 231 | 229 | 227 | 208 | Upgrade
|
| Shares Outstanding (Diluted) | 252 | 231 | 229 | 227 | 208 | Upgrade
|
| Shares Change (YoY) | 8.85% | 0.88% | 0.72% | 9.33% | 22.57% | Upgrade
|
| EPS (Basic) | 0.52 | 0.82 | 1.96 | 1.41 | 0.81 | Upgrade
|
| EPS (Diluted) | 0.52 | 0.82 | 1.96 | 1.41 | 0.81 | Upgrade
|
| EPS Growth | -36.59% | -58.16% | 39.31% | 73.99% | 13.35% | Upgrade
|
| Free Cash Flow | - | -723.72 | -967.75 | -98.92 | -84.93 | Upgrade
|
| Free Cash Flow Per Share | - | -3.13 | -4.22 | -0.43 | -0.41 | Upgrade
|
| Dividend Per Share | - | 0.250 | 0.621 | 0.428 | 0.262 | Upgrade
|
| Dividend Growth | - | -59.72% | 44.99% | 63.33% | 63.51% | Upgrade
|
| Gross Margin | 100.00% | 24.78% | 40.36% | 38.66% | 32.29% | Upgrade
|
| Operating Margin | 4.36% | 9.59% | 25.62% | 22.35% | 17.72% | Upgrade
|
| Profit Margin | 4.53% | 8.70% | 23.17% | 22.56% | 17.63% | Upgrade
|
| Free Cash Flow Margin | - | -33.23% | -49.93% | -6.97% | -8.90% | Upgrade
|
| EBITDA | 264.48 | 347.41 | 595.44 | 376.25 | 216.56 | Upgrade
|
| EBITDA Margin | 9.16% | 15.95% | 30.72% | 26.52% | 22.70% | Upgrade
|
| D&A For EBITDA | 138.66 | 138.66 | 98.84 | 59.15 | 47.5 | Upgrade
|
| EBIT | 125.82 | 208.75 | 496.6 | 317.1 | 169.06 | Upgrade
|
| EBIT Margin | 4.36% | 9.59% | 25.62% | 22.35% | 17.72% | Upgrade
|
| Effective Tax Rate | - | 8.37% | 11.79% | 6.89% | 11.82% | Upgrade
|
| Revenue as Reported | - | 2,178 | 1,938 | 1,419 | 954.1 | Upgrade
|
| Advertising Expenses | - | 4.84 | 3.33 | 1.33 | 0.7 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.